BioCentury | Oct 9, 2020
Finance

Kronos’ post-IPO gains build on $1B+ postmoney valuation

...steatohepatitis and myelofibrosis.  TARGETSCD40L (CD40LG; CD154) - CD40...
BioCentury | Jul 15, 2020
Product Development

University of Queensland COVID-19 vaccine becomes seventh with CEPI funding to enter the clinic

...is partnered with Fosun Pharmaceutical Group Co. Ltd. (Shanghai:600196; HKEX:2196). Targets CD40L (CD40LG; CD154) - CD40...
BioCentury | Jun 19, 2020
Deals

In second innovative deal this month, AbbVie gains option to Alpine’s ‘first-in-class’ lupus program

...the co-stimulatory receptor CD40L, which is primarily expressed on T cells, preventing its interaction with CD40...
...cells and B cells. Durand said that while Alpine has not directly compared ALPN-101 to CD40/CD40L...
BioCentury | Jun 16, 2020
Finance

eTheRNA’s €34M series B to support different take on COVID-19 vaccine, build out core cancer pipeline

...of the deal and financial terms were still being finalized. Targets CD40L (CD40LG; CD154) - CD40...
BioCentury | May 29, 2020
Finance

May 28 Quick Takes: Illumina leads $70M Ginkgo round; plus Arena, Viela Bio, BioCryst, Progenity and Microbion

...undisclosed. The candidate has Orphan Drug and Fast Track designations. Targets CD40L (CD40LG; CD154) - CD40...
BioCentury | Mar 25, 2020
Finance

March 24 Quick Takes: Apexigen brings series C to $123M; plus Nanjing F&S, FCA and Asieris

...Oceanpine Capital, with participation from undisclosed new and existing investors. The immuno-oncology company's lead candidate, anti-CD40...
BioCentury | Mar 7, 2020
Emerging Company Profile

Kira: depleting activated dendritic cells

...programs that seek to deplete activated dendritic cells. However, other activated dendritic cell markers including CD40...
...CD86 and CD80. According to BioCentury’s BCIQ database, there are at least six companies with CD40...
...Janus kinase-1 JAK-2 - Janus kinase-2 Hongjiang Li, Staff Writer Bruton's tyrosine kinase (Btk) CD83 Janus kinase-2 (JAK-2) Janus kinase-1 (JAK-1) Calcineurin CD40 CD80...
BioCentury | Feb 29, 2020
Product Development

Coming competition in myasthenia gravis

...its blockade would reduce B cell activation and differentiation into antibody-producing plasma cells. Blockade of CD40...
...the early part of the disease pathway, preventing autoantibody production. Their targets were BAFF and CD40...
BioCentury | Feb 1, 2020
Company News

BioNTech’s approach to matching technologies to tumors

...DuoBody technology from Genmab A/S (CSE:GMAB; NASDAQ:GMAB). BNT311 targets PD-L1 and 4-1BB, while BNT312 targets CD40...
BioCentury | Jan 25, 2020
Tools & Techniques

Manufacturing roundup: Deerfield launches new CDMO, plus a gene/cell therapy JV and more

...to treat metastatic pancreatic cancer. The therapy incorporates an inducible co-activation domain comprising MYD88 and CD40...
Items per page:
1 - 10 of 331